Consult Super-Specialist Doctors at CARE Hospitals
The triple marker test, also known as the triple screen test, is a prenatal blood screening that detects the risk of genetic abnormalities in the foetus. This test measures the levels of three substances - alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and unconjugated estriol (uE3) - in the pregnant woman’s blood.
The triple marker screening calculates the probability of the foetus having a chromosomal abnormality or a neural tube defect. It does not diagnose a definitive disorder. If the chances are high, the doctor recommends diagnostic tests to confirm.
The triple marker test primarily screens for major genetic issues in the foetus, such as:
The test calculates, based on maternal blood markers, whether the foetus falls into a high or low-risk zone for these common chromosomal issues.
Doctors recommend the triple marker test for pregnant women who:
The test is much like a regular blood draw. A tourniquet is tied, the blood draw site is cleaned, and the nurse inserts the needle to extract blood into attached vials. This blood sample is then sent to the laboratory for analysis. There is no significant physical discomfort during or after the test.
The test allows parents and doctors to stay vigilant and make informed choices regarding prenatal care. It empowers parents to equip themselves to welcome a child who may require extra medical or social support.
Before the Test
During the Test
After the Test
Since it only involves a blood draw, no specific preparation is needed. But, in general:
Getting adequate rest and nutrition optimises your well-being and supports proper growth of the foetus.
Normal Range:
Positive Test Result:
Negative Test Result:
Here’s the difference between double marker and triple marker test:
The triple marker test is more expansive as it analyses one additional hormone. This provides greater precision in determining genetic disorder risks. It has lower false positive rates and higher detection rates.
The triple marker test allows pregnant women to assess the odds of their baby having major chromosomal anomalies or neural tube issues. Under expert guidance, the test empowers parents to optimise health outcomes through timely interventions. While no prenatal test is completely accurate, the triple screen offers vital insights for attentive and proactive prenatal care.
Ans: AFP level between 0.5-2.5 MoM is considered normal. Above 2.5 MoM indicates elevated risk, and hence you must visit your doctor.
Ans: A positive test means a high risk for genetic issues. Further invasive diagnostic testing is required to confirm a chromosomal disorder. Amniocentesis and chorionic villus sampling are confirmatory prenatal tests.
Ans: A negative result suggests a lower chance of disorders. But, it can not guarantee that there won't be any disorders. Repeat tests may be necessary if the doctor suspects potential issues.
Ans: The ideal time for triple marker testing is between 15 to 20 weeks of pregnancy. This allows the hormones to rise to measurable levels in the blood. Testing too early can give unreliable results with many false positives. The hormones peak between weeks 15-18, making it the optimal screening window.